Department of Biopharmacy, Medical University of Lublin, Poland.
Independent Laboratory of Behavioral Studies, Medical University of Lublin, Poland.
Eur Neuropsychopharmacol. 2021 Nov;52:31-47. doi: 10.1016/j.euroneuro.2021.06.006. Epub 2021 Jul 6.
The aim of this study is to determine whether type I and type II positive allosteric modulators (PAMs) of α7 nicotinic acetylcholine receptors (nAChRs) induce antidepressant-like activity in mice after acute, subchronic, and chronic treatments, and to assess whether α7-PAMs inhibit neurotransmitter transporters and activate mTOR (mammalian target of rapamycin) and/or ERK (extracellular signal-regulated protein kinases) signaling. The forced swim (FST) and tail suspension (TST) test results indicated that NS-1738 (type I PAM), PNU-120596 and PAM-2 (type II PAMs) induce antidepressant-like activity after subchronic treatment, whereas PAM-2 was also active after chronic treatment. Methyllycaconitine (α7-antagonist) inhibited the observed effects, highlighting the involvement of α7 nAChRs in this process. Drug interaction studies showed synergism between PAM-2 and bupropion (antidepressant), but not between PAM-2 and DMXBA (α7-agonist). The studied PAMs showed no high affinity (< 1 µM) for the human dopamine, serotonin, and noradrenaline transporters, suggesting that transporter inhibition is not the underlying mechanism for the observed activity. To assess whether mTOR and ERK signaling pathways are involved in the activity of α7-PAMs, the phosphorylation status of key signaling nodes was determined in prefrontal cortex and hippocampus from mice chronically treated with PAM-2. In conclusion, the antidepressant-like activity of type I and type II PAMs is mediated by a mechanism involving α7 potentiation but not α7 desensitization or neurotransmitter transporter blockade, and is correlated with activation of both mTOR and ERK signaling pathways. These results support the view that α7-PAMs might be clinically used to ameliorate depression disorders .
本研究旨在确定 I 型和 II 型 α7 烟碱型乙酰胆碱受体 (nAChR) 正变构调节剂 (PAMs) 在急性、亚慢性和慢性治疗后是否能在小鼠中诱导抗抑郁样活性,并评估 α7-PAMs 是否抑制神经递质转运体并激活 mTOR(哺乳动物雷帕霉素靶蛋白)和/或 ERK(细胞外信号调节蛋白激酶)信号通路。强迫游泳(FST)和悬尾(TST)测试结果表明,NS-1738(I 型 PAM)、PNU-120596 和 PAM-2(II 型 PAMs)在亚慢性治疗后诱导抗抑郁样活性,而 PAM-2 也在慢性治疗后具有活性。甲基金刚烷(α7 拮抗剂)抑制了观察到的作用,突出了 α7 nAChR 在这一过程中的作用。药物相互作用研究表明,PAM-2 与丁胺苯丙酮(抗抑郁药)之间存在协同作用,但 PAM-2 与 DMXBA(α7 激动剂)之间不存在协同作用。研究的 PAMs 对人多巴胺、血清素和去甲肾上腺素转运体没有高亲和力(<1µM),表明转运体抑制不是观察到的活性的潜在机制。为了评估 mTOR 和 ERK 信号通路是否参与 α7-PAMs 的活性,测定了慢性给予 PAM-2 的小鼠前额叶皮层和海马中的关键信号节点的磷酸化状态。总之,I 型和 II 型 PAMs 的抗抑郁样活性是通过一种涉及 α7 增强但不涉及 α7 脱敏或神经递质转运体阻断的机制介导的,与 mTOR 和 ERK 信号通路的激活相关。这些结果支持了 α7-PAMs 可能在临床上用于改善抑郁症的观点。